lterations in type I and type II oncostatin M receptor expression in the pathogenesis of non-alcoholic fatty liver disease

2018 ◽  
Author(s):  
P Lederer ◽  
A Geier ◽  
HM Hermanns
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Receptor Expression ◽  
Oncostatin M ◽  
Type I ◽  
Type Ii ◽  
Alcoholic Fatty Liver ◽  
Oncostatin M Receptor ◽  
Alcoholic Fatty Liver Disease

FRI-317-Progression of fatty liver disease to steatohepatitis and liver fibrosis is associated with altered Oncostatin M type I and type II receptor expression

2019 ◽  
Vol 70 (1) ◽  
pp. e536
Author(s):  
Philipp Lederer ◽  
Martin Roderfeld ◽  
Daniela Kroy ◽  
Elke Roeb ◽  
Andreas Geier ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Receptor Expression ◽  
Oncostatin M ◽  
Type I ◽  
Type Ii

Su1633 HUMAN ACTIVITY PROFILE IN THE CONTEXT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND TYPE II DIABETES MELLITUS (DM)

2020 ◽  
Vol 158 (6) ◽  
pp. S-1365-S-1366
Author(s):  
James M. Estep ◽  
Jillian Kallman Price ◽  
Leyla de Avila ◽  
Carey Escheik ◽  
Aybike Birerdinc ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Type Ii Diabetes ◽  
Fatty Liver Disease ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Activity Profile ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Therapeutic Effect of Puerarin on Non-Alcoholic Rat Fatty Liver by Improving Leptin Signal Transduction through JAK2/STAT3 Pathways

2009 ◽  
Vol 37 (01) ◽  
pp. 69-83 ◽  
Author(s):  
Peiyong Zheng ◽  
Guang Ji ◽  
Zansong Ma ◽  
Tao Liu ◽  
Lianjun Xin ◽  
...  
Keyword(s):  
Signal Transduction ◽  
Liver Disease ◽  
Fatty Liver ◽  
Therapeutic Effect ◽  
Fatty Liver Disease ◽  
Receptor Expression ◽  
Male Rat ◽  
Group Model ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

In order to investigate the mechanism of the therapeutic effect of puerarin on non-alcoholic fatty liver disease, a non-alcoholic fatty disease male rat model was induced by a high fat diet, all rats were randomly divided into a blank group, model group, simavastatin group and puerarin group. After 4 weeks of drug treatment, the liver was slided to investigate pathological morphology. Elisa was used to measure the total cholesterol (TC), triglyeride (TG) in liver, and leptin content in serum. RT-PCR and Western blotting were employed to detect liver leptin mRNA receptor expression and P-JAK2, P-STAT3 expression levels in the liver respectively. The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level. All the results demonstrated that puerarin can exhibit therapeutic effect on non-alcoholic fatty liver disease by improving leptin signal transduction through JAK2/STAT3 pathways.

Sign in / Sign up

Export Citation Format

Share Document